Antagonistic peptide technology for functional dissection of CLE peptides revisited.
Antagonistic peptide technology for functional dissection of CLE peptides revisited.
复制标题
DOI：
10.1093/jxb/erv284
复制
发表时间：
2015-08
影响因子：
6.9
通讯作者：
De Smet I
中科院分区：
文献类型：
--
作者：
Czyzewicz N;Wildhagen M;Cattaneo P;Stahl Y;Pinto KG;Aalen RB;Butenko MA;Simon R;Hardtke CS;De Smet I
使用拮抗肽方法收集的信息可能非常有用，但这些方法并不适用于所有情况，需要深入了解配体-受体相互作用和肽配体结构。在拟南芥基因组中，超过1000个推定的基因编码小，大概分泌，信号肽可以识别。然而，在确定编码小信号肽的基因的功能中的主要障碍是可用的功能丧失突变体的数量有限。为了克服这一点，最近开发了一种有前途的新工具，拮抗肽技术。在这里，这种拮抗肽技术进行了测试，选择CLE肽和相关的IDA肽和它的有用性的背景下，肽功能的研究进行了讨论。基于分析，得出结论，拮抗肽方法不是克服冗余或缺乏功能丧失系的最终手段。然而，使用拮抗肽方法（广义上）收集的信息可能非常有用，但这些方法并不适用于所有情况，需要深入了解配体及其受体之间的相互作用才能成功。在订购各种合成肽变体和/或生成转基因植物之前，应考虑到这一点以及肽配体结构的考虑因素。
Information collected using antagonistic peptide approaches can be very useful, but these approaches do not work in all cases and require insight on ligand-receptor interactions and peptide ligand structure. In the Arabidopsis thaliana genome, over 1000 putative genes encoding small, presumably secreted, signalling peptides can be recognized. However, a major obstacle in identifying the function of genes encoding small signalling peptides is the limited number of available loss-of-function mutants. To overcome this, a promising new tool, antagonistic peptide technology, was recently developed. Here, this antagonistic peptide technology was tested on selected CLE peptides and the related IDA peptide and its usefulness in the context of studies of peptide function discussed. Based on the analyses, it was concluded that the antagonistic peptide approach is not the ultimate means to overcome redundancy or lack of loss-of-function lines. However, information collected using antagonistic peptide approaches (in the broad sense) can be very useful, but these approaches do not work in all cases and require a deep insight on the interaction between the ligand and its receptor to be successful. This, as well as peptide ligand structure considerations, should be taken into account before ordering a wide range of synthetic peptide variants and/or generating transgenic plants.